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ABSTRACT: Genetic testing for hypertrophic cardiomyopathy (HCM) is an established clinical technique, supported by 30 years 
of research into its genetic etiology. Although pathogenic variants are often detected in patients and used to identify at- risk 
relatives, the effectiveness of genetic testing has been hampered by ambiguous genetic associations (yielding uncertain and 
potentially false- positive results), difficulties in classifying variants, and uncertainty about genotype- negative patients. Recent 
case- control studies on rare variation, improved data sharing, and meta- analysis of case cohorts contributed to new insights 
into the genetic basis of HCM. In particular, although research into new genes and mechanisms remains essential, reassess-
ment of Mendelian genetic associations in HCM argues that current clinical genetic testing should be limited to a small number 
of validated disease genes that yield informative and interpretable results. Accurate and consistent variant interpretation has 
benefited from new standardized variant interpretation guidelines and innovative approaches to improve classification. Most 
cases lacking a pathogenic variant are now believed to indicate non- Mendelian HCM, with more benign prognosis and mini-
mal risk to relatives. Here, we discuss recent advances in the genetics of HCM and their application to clinical genetic testing 
together with practical issues regarding implementation. Although this review focuses on HCM, many of the issues discussed 
are also relevant to other inherited cardiac diseases.
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Hypertrophic cardiomyopathy (HCM) is an inher-ited disease of cardiac muscle characterized by substantial heterogeneity in morphology, clin-
ical manifestation, genetic etiology, and outcome.1 
HCM is diagnosed in the presence of a maximum 
left- ventricular wall thickness of at least 15 mm when 
this is not solely explained by abnormal loading condi-
tions (such as hypertension and aortic stenosis), with 
other typical features including myocyte disarray and 
interstitial fibrosis.2 Although HCM is considered a 
Mendelian disease with largely autosomal dominant 
inheritance, incomplete penetrance and variable ex-
pressivity are commonly observed in affected families.
As well as being a relatively common (estimated 
to affect 1 in 500 people)2–4 and medically important 
condition, HCM has been an important model disease 
for studying issues that are shared among many in-
herited cardiac diseases. Research into the genetic 
basis of HCM has been ongoing for almost 30 years 
and early implementation of clinical genetic testing has 
yielded extensive data sets for use in research stud-
ies. However, several issues have limited the impact of 
HCM genetic testing in clinical practice:
1. Over half of patients tested have a negative genetic 
test result (ie, no definitive or putative pathogenic 
variant is detected).
2. The significance of many detected variants has been 
difficult to ascertain.
3. The limited correlation between genotype and clini-
cal phenotype has constrained the use of genetic 
knowledge in directing clinical management.
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4. The ever-increasing number of genes apparently as-
sociated with disease has clouded our understand-
ing of the genetic architecture of HCM.
Despite these open challenges, recent findings 
have transformed our understanding of the genetic 
basis of HCM and offered the potential for more ac-
curate, sensitive, and impactful application of genetic 
testing. These findings have been driven by the devel-
opment of population genetic databases that have rev-
olutionized our understanding of rare genetic variation 
in health and disease and by the accumulation of large 
patient cohorts and disease registries. Collaborative 
models of data sharing, together with the development 
of consensus guidelines for variant interpretation and 
validation of disease- gene associations, have proven 
invaluable for improving our knowledge of rare genetic 
diseases.
Here, we discuss the achievements earned in un-
derstanding the genetics of HCM in the past 30 years, 
the clinical implications of the current reassessment 
of genetic associations, the need to manage the 
genotype- negative HCM patient in a coherent and 
effective manner, and the challenges that need to be 
addressed before we can adopt a patient- specific, 
individualized approach in HCM. While focusing on 
HCM, the issues discussed are also broadly relevant 
to our understanding of other cardiomyopathies and 
inherited cardiac diseases.
GENETIC ASSOCIATIONS
HCM was first recognized over 50 years ago as a fa-
milial myocardial disease with increased risk for sud-
den death, variable disease expressivity, and natural 
history.5,6 After more than 2 decades during which 
the cause of HCM remained unknown, the dawn of a 
molecular era arrived in 1989, when the first genetic 
locus (14q1) associated with the condition was de-
tected by means of a linkage analysis on a large kin-
dred group comprising 96 individuals and spanning 
4 generations.7 Shortly after, the associated genomic 
region was narrowed further by additional linkage 
studies on the same family, restricting the region 
containing the genetic defect to locus 14q11- 12,8 and 
consequently defining a potential causal role for one 
of the two highly homologous genes encoding myo-
sin heavy chains: MYH6 and MYH7. The responsible 
gene was identified the same year as MYH7, with the 
identification of the causative missense substitution 
p.Arg403Glu.9 The same month, another study from 
the same research group was published to dem-
onstrate the genetic heterogeneity of HCM, as co- 
segregation of variants at the MYH7 locus with HCM 
was observed in only 2 of 4 affected pedigrees, high-
lighting the existence of alternative genetic causes at 
other loci.10
After these pivotal discoveries, the genetic rep-
ertoire of HCM was gradually expanded throughout 
the decade to include seven additional sarcomeric 
genes (MYBPC3, TNNT2, TPM1, MYL2, MYL3, 
TNNI3, ACTC1)7–19 (Table 1), incontrovertibly associ-
ated with HCM by studies based on linkage analyses 
in large and/or multiple affected families and func-
tional experiments. We refer to these eight “core” 
disease genes with the term “validated genes” in 
this review. Simultaneously, definitive genetic as-
sociations with genocopies of HCM (ie, metabolic 
diseases characterized by a phenotype mimicking 
HCM but caused by genetic variants in different 
genes) were demonstrated, starting with Pompe dis-
ease20–33 (Table  2). Besides Pompe disease, Fabry 
disease, PRKAG2- cardiomyopathy, Danon disease, 
and TTR- amyloidosis, other conditions (due to mito-
chondrial dysfunctions) can seldom present resem-
bling isolated HCM, such as Friedreich’s ataxia and 
Leigh syndrome, caused by variants in the FXN and 
COX15 genes, respectively.
Improvements in sequencing technologies and 
their throughput, particularly with the advent of next- 
generation sequencing (NGS), revolutionized the abil-
ity to investigate the genetic architecture of Mendelian 
diseases such as HCM. Case- control rare variant 
comparisons became the design of choice for most 
studies, where usually relatively small groups of pa-
tients and controls were sequenced on one or a few 
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Molecular Medicine
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Information
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genes of interest, encoding proteins within or outside 
the sarcomere, implicated in HCM with varying levels 
of supportive evidence48,49 (Figure 1).
Whenever a protein- altering variant was observed 
uniquely in patients, the absence of such variants in 
controls was often used as stand- alone evidence in 
support of the claim for pathogenicity, with little con-
vincing segregation or functional evidence in support. 
Although at the time these approaches were generally 
considered sufficient to implicate genes in Mendelian 
disease, it is now recognized that more substantial 
evidence is necessary to demonstrate association be-
tween variants in a given gene and disease.
The consequence of these efforts was an exponen-
tial increase in the number of proposed genetic associ-
ations in the years between 2000 and 2015 (Figure 2). 
By 2016, 64 genes had been claimed to be causative 
in HCM (Human Gene Mutation Database v.2016.3, 
Table S1) with few of the additional genes being sup-
ported by sufficiently comprehensive and robust evi-
dence50–57 (Table 3).
Population databases of whole- exome sequenc-
ing (WES)—and in part, whole- genome sequencing 
(WGS)—such as the 1000 Genomes Project58 (≈2500 
individuals) and National Heart, Lung, and Blood 
Institute Exome Sequencing Project59 (ESP, ≈6500 in-
dividuals) enabled early observations that many vari-
ants previously associated with cardiomyopathies were 
instead likely benign, as their population frequencies 
were incompatible with the prevalence of disease.60,61 
The definitive proof of this arrived in October 2014 with 
the release of the Exome Aggregation Consortium 
(ExAC) data set, a large collation of WES data from 
over 60 000 individuals,62 in which the average indi-
vidual was shown to carry ≈54 variants previously 
reported as pathogenic in widely used databases of 
disease- causing variants.
In the case of HCM and dilated cardiomyopathy 
(DCM), large- scale analysis based on ExAC demon-
strated that the frequency of rare variants found in 
many genes implicated in the condition was compara-
ble to background population variation,49,63,64 casting 
doubts on the veracity of many purported associations 
(Figure 2). In addition, a number of independent dis-
ease- and gene- specific approaches have recently 
been developed to aid decisions on which genes to 
include in clinical diagnostic panels. One recent exam-
ple is the diagnostic effectiveness (DEff ),65 a gene- and 
disease- specific metric combining measures of ac-
tionability for cascade screening and prior likelihood 
of pathogenicity of variation detected in patients. DEff 
scores of validated and putative disease genes can be 
compared, in order to assist the decision on which of 
the latter should be routinely assessed in clinical prac-
tice and which would yield, at most, inconclusive re-
sults (variants of uncertain significance).
Table 1. Breakdown of the Original Linkage Studies Demonstrating the Co- Segregation of Genetic Variants and 







(Total Size) Max LOD Notes
MYH7 Beta- myosin heavy 
chain
Locus 14q1 1989 7 AD 1 (96) 9.37 ···
Locus 14q11- 12 1990 8 1 (96) 4.62 ···
Gene 1990 9 1 (96) 15.9 ···
Genetic heterogeneity 
of HCM
1990 10 4 (173) 10.85 ···
TNNT2 Cardiac troponin T Locus 1q3 1993 11 AD 3 (97) 8.47 ···
Gene 1994 12 1 (70) 6.3 ···
MYBPC3 Myosin- binding 
protein C
Locus 11p13- q13 1993 13 AD 1 (54) 4.98 ···
Gene 1995 14 2 (46) 3.74 ···
TPM1 Alpha tropomyosin Locus 15q2 1993 15 AD 2 (87) 6.02 ···
Gene 1994 12 2 (87) 6.94 ···
MYL3 Essential myosin 
light chain 3
Gene 1996 16 AD 1 (53) 6.2 ···
TNNI3 Cardiac troponin I Gene 1997 17 AD 1 (18) 3.1 ···
MYL2 Regulatory myosin 
light chain 2
Gene 1998 18 AD 3 (47) 2.41 
(estimated)
*
ACTC1 Alpha actin (cardiac 
muscle) 1
Gene 1999 19 AD 1 (22) 3.6 ···
AD indicates autosomal dominant; and HCM, hypertrophic cardiomyopathy.
*Although an LOD score of 2.41 is below the universally accepted threshold of LOD=3 for co- segregation to be considered unequivocal, in the years following 
this original association with HCM, further evidence about the gene’s disease- causing role in HCM gradually accumulated,20–22 and collectively made the 
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Rigorous, disease- specific gene curation efforts 
that assess all available lines of evidence for disease 
association are now essential for genetically hetero-
geneous Mendelian diseases like HCM. In spite of 
the lack of a standardized approach to weight differ-
ent types of evidence for gene- disease associations, 
results obtained by curation/classification efforts are 
characterized by general concordance, with the 8 
validated genes unanimously considered as incon-
trovertibly associated with HCM, and genes such 
as PLN and CSRP3 supported by strong evidence 
in favor of HCM pathogenicity.48,49,65 The ClinGen 
initiative66 (https://clini calge nome.org/)—founded to 
define the clinical relevance of genes and genetic 
variants—has recently established a framework to 
systematically assess all gene- disease claimed as-
sociations’ veracity and their clinical validity based 
on published evidence. The curation effort for HCM, 
assessing >50 genes, has recently classified evi-
dence in support of their role in HCM as “definitive” 
for the 8 validated sarcomeric genes, PLN and FLNC 
(also associated with myofibrillar myopathy), “strong” 
for ALPK3 and “moderate” for ACTN2, CSRP3, 
TNNC1 and JPH2 (Tables 1 and 3).48 Other 20 genes 
were assigned a ≥ moderate evidence classification 
for their role in genocopies of HCM (Table 2) or syn-
dromes involving HCM.
GENETIC TESTING STRATEGIES
The primary purpose of genetic testing in HCM is to 
facilitate cascade screening in relatives of the index 
patient in order to identify those at risk and those not 
at risk of developing disease. As guidelines currently 
recommend regular clinical evaluation for first- degree 
relatives of all HCM patients,2 discharging those rela-
tives lacking identified pathogenic variants offers 
obvious psychological benefits for these individuals 
and significant cost savings for healthcare providers. 
Genetic testing for HCM has been shown to be more 
cost effective than clinical screening alone in UK67 
and Australian68 studies, and the Partners Laboratory 
for Molecular Medicine (LMM) estimated savings of 
USD 700  000 (based on Medicare rates) from dis-
charging genotype- negative relatives of 2912 HCM 
probands.69 Ongoing reductions in the costs of DNA 
sequencing, and improvements in variant analysis 
as described subsequently, will further support the 
economic case for HCM genetic testing. It has also 
Table 2. List of the Genetic Associations With Metabolic/Infiltrative Genocopies of HCM, Originally Demonstrated Through 
the Collation of Different Types of Evidence (See References and Notes), Alongside the Main Currently Available Treatment 
Options
Gene Protein Disease Year(s) Reference No. Inheritance Main Treatment Options Notes
GAA Glucosidase 
alpha








1989–1994 27–29 X Antiplatelet/anticoagulant 
agents, enzyme- 
replacement therapy, 







Danon disease 2004–2007 30–32 X ICD implantation ‡







2001 33 AD Antiarrhythmic drugs, 
ablation
§
TTR Transthyretin Transthyrethin 
amyloidosis
1991–2002 34–37 AD Liver/kidney/heart 
transplantation
∥
Of note, 15 other genes (including RASopathy genes such as PTPN11 and RAF1) have been classified as with ≥ moderate evidence by ClinGen for 
syndromic conditions where HCM can be seen. RASopathy genes are not included in the “genocopies of HCM” category as diagnostic discrimination between 
RASopathies and HCM is usually easier, due to the systemic features of the former (although in rare cases they may still resemble isolated HCM). AD indicates 
autosomal dominant; AR, autosomal recessive; HCM, hypertrophic cardiomyopathy; ICD, implantable cardioverter- defibrillator; and X, X- linked.
*Other reports38–40 determined the gene sequence and contributed to show that the disease was due to a lack of alpha- glucosidase.
†Other reports41,42 determined the gene sequence and contributed to show that the disease was due to a lack of alpha- galactosidase.
‡Reports by Danon et al43 and Nishino et al44 described Danon disease as a distinct lysosomal glycogen storage disease and showed that the cause was a 
deficiency of lysosome- associated membrane protein 2.
§The reported study (Gollob et al33) consisted of a linkage analysis on two pedigrees including 70 individuals, with a LOD score for co- segregation of variants 
in PRKAG2 and disease of 9.82.
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been recognized that genetic testing in probands 
can increase the often low take- up in clinical screen-
ing from at- risk relatives.70
In contrast, knowledge of the causative genetic vari-
ant does not currently affect the clinical management 
for most HCM patients and is not included in sudden 
cardiac death (SCD) risk assessment models.71,72 The 
exception to this is identifying patients with pathogenic 
variants in a small group of genes—such as GAA, GLA, 
LAMP2, PRKAG2 and TTR—that are incontrovertibly 
associated with metabolic diseases that mimic HCM 
(Figure 1 and Table 2) but have distinctive clinical pro-
files, inheritance patterns, and treatment options.73 
The inclusion of these genes in diagnostic panels for 
HCM is advantageous given their pronounced pheno-
typic similarity with the classic sarcomeric form74 and 
the importance of a prompt differential diagnosis, en-
abling correct treatment decisions and optimal patient 
management and de facto representing a significant 
step toward more personalized approaches.
Despite limited evidence for a causal role in HCM, 
many of the non- sarcomeric genes implicated in the 
disease have been progressively included in panels 
developed by clinical laboratories and commercial pro-
viders75 (listed in the National Center for Biotechnology 
Information Genetic Testing Registry: https://www.ncbi.
nlm.nih.gov/gtr/). The uncertainty around the pathoge-
nicity of these “genes of uncertain significance” in HCM 
has led to difficulty for clinical diagnostic laboratories in 
choosing which of the ambiguous genes to include in 
routinely used diagnostic panels. The choice ultimately 
lies on the spectrum between the extremes of including 
only the validated genes at one end (bottom left and bot-
tom right panels in Figure 1) and systematically screening 
all genes implicated in HCM at the other, irrespective of 
the strength of evidence in support of their causal role for 
Figure  1. Examples of molecular complexes and proteins of the cardiomyocyte encoded by genes associated with 
sarcomeric HCM, its mimics and syndromic conditions featuring HCM with different levels of supporting evidence.
Strength of evidence in favor of pathogenicity (top right panel) is coded as in the curation effort by the ClinGen consortium.48 Details 
about genetic associations for definitive genes displayed in the bottom left and bottom right panel, and genes with ≥ moderate 
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HCM. The former, conservative choice plausibly leads 
to the possibility of false negative genetic tests but the 
latter, inclusive option, bears greater potential for false 
positive results, which can be detrimental for the patients 
and their family members, and increases the uncertainty 
associated with testing through an epidemic of variants 
of unknown significance (VUS). Unsurprisingly, expand-
ing HCM panels to include genes of questionable patho-
genicity has had little effect on the sensitivity of genetic 
testing. For example, LMM reported identifying only one 
pathogenic variant in 632 cases (in the PLN gene) out-
side of the 8 core sarcomeric genes and metabolic car-
diomyopathy genes.69
Ongoing reductions in the cost of sequencing have 
meant that WGS (complete sequencing of the entire 
genome in an individual) and WES (sequencing of the 
1% of the genome that encodes proteins) may become 
feasible options as first- line sequencing assays in the 
near future. However, there is limited evidence that 
WGS and WES are currently cost effective in clinical 
practice.76 For example, a recent study that was part of 
the Medseq initiative to evaluate the clinical potential of 
WGS77 compared the performance of a targeted gene 
panel and WGS in 41 HCM patients. WGS identified 
19 of the 20 variants of interest detected by panel se-
quencing, but missed a 18 bp duplication in MYBPC3 
due to low coverage and only additionally identified a 
causative variant in a RASopathy gene (not in the panel) 
as well as several VUS and secondary findings. The 
limited value of WGS, WES, or super- sized gene panels 
for standard HCM genetic testing, that is, adult- onset 
and/or autosomal dominant disease in the absence of 
Figure 2. Number of genes implicated in HCM in the literature with different levels of supporting 
evidence (black line, left y axis) ranging from fully validated genes (darker green line) to those 
without substantial evidence supporting pathogenicity.
The black line indicates the number of scientific publications in PubMed featuring next- generation 
sequencing (colored lines, right y axis). The classification criteria for evidence in favor of pathogenicity 
(as detailed in the legend) and the genes included (n=39) reflect the analysis and curation effort by Walsh 
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large family pedigrees, is clear when considering cur-
rent variant interpretation guidelines for clinical testing 
and the requirements for defining a variant as action-
able (see next section). It will be impossible to classify 
a variant in a novel gene as clinically actionable in the 
vast majority of cases, regardless of how plausible that 
candidate gene may be, as the guidelines require as a 
minimum that the gene or variant class has a proven 
role in the disease.
In contrast, WGS/WES can offer some advantages 
as diagnostic sequencing assays if testing is restricted 
to genes and regions that have been validated for 
the disease in question. In this “virtual panel testing” 
approach, analysis is restricted to only those genes 
that can yield interpretable variants, but the exten-
sive sequencing enables reanalysis of archived data 
as new and validated gene- disease associations are 
published, as well as potentially generating compre-
hensive and useful data sets for research purposes. 
One advantage of WGS compared with approaches 
targeting only protein- coding regions of genes (eg, 
targeted gene panel and WES) is its enhanced abil-
ity to identify variants classes such as copy number 
variants (CNVs)—deletions or duplications of whole 
exons, genes, or chromosomal regions—and variants 
in noncoding regions of the genome such as introns. 
Studies exploring the role of CNVs in HCM have found 
such variation in ≈1% of cases,78–80 although detecting, 
validating, and interpreting CNVs remains a challeng-
ing and nonstandardized task. A recent study used 
WGS to identify deep intronic variants in MYBPC3 in 4 
HCM patients who were negative for standard genetic 
testing, and these variants were shown to affect splicing 
and produce truncated transcripts.81 The contribution 
of these noncoding variants that affect gene dosage 
is likely to be particularly relevant to genes where the 
underlying disease mechanism is haploinsufficiency 
(ie, where the loss of half of the physiological amount 
of functional protein causes disease). This is often the 
case for genes in which protein- truncating variants are 
the most prevalent pathogenic variant class although, 
in the case of MYBPC3, haploinsufficiency has also 
been proposed as the molecular mechanism for sev-
eral missense variants.82 For most of the other major 
sarcomeric HCM genes where variants act in a dom-
inant negative manner, such noncoding variants are 
expected to be less relevant.
In addition to these scientific pros and cons, other 
factors such as affordability and the quality and tech-
nical features of generated data are also important 
factors in choosing a sequencing platform for genetic 
testing.83,84 As highlighted previously, depth of cover-
age for affordable WGS/WES in the diagnostic setting 
may currently be inferior to panel sequencing and lead 
to false negative findings—this is particularly relevant 
for WES assays as some exons, especially in GC- rich 
regions, are not adequately captured.85 It is also im-
portant to recognize the extra burden of data process-
ing, analysis, and storage associated with WGS/WES, 
as well as ethical issues relating to secondary and in-
cidental findings if analysis is not restricted to valid dis-
ease genes for the primary condition.
At present, the primary role for unbiased WGS/WES 
lies in the research setting in order to identify putative 
Table 3. Other Genes Classified as With Moderate/Strong/Definitive Evidence for Isolated HCM (or Multiple Conditions 
Including Isolated HCM) by ClinGen,48 or With Convincing Evidence for HCM Causation Published After the ClinGen 
Curation Effort
Gene Protein Disease Year Reference No. Inheritance
ClinGen 
Classification Notes
TNNC1 Troponin C type 1 (slow) Isolated HCM 2001 36 AD Moderate ···
PLN Phospholamban HCM, DCM, and ARVC 2003 37 AD Definitive ···
CSRP3 Cysteine and glycine- rich 
protein 3 (cardiac LIM 
protein)
Isolated HCM 2003 38 AD Moderate ···
JPH2 Junctophilin 2 Isolated HCM 2007 39 AD Moderate ···
ACTN2 Actinin, alpha 2 HCM, LVH, LVNC, 
DCM, idiopathic VF
2010 40 AD Moderate ···
FLNC Filamin C, gamma HCM, myofibrillar 
myopathy
2014 41 AD Definitive ···
ALPK3 Alpha- kinase 3 HCM, DCM 
(infant- onset)
2016 42 AR Strong ···
FHOD3 Formin homology 2 
domain containing 3
HCM 2018 43 AD ··· *
The year and reference reported refer to the main publication in which a disease- causing role in HCM was proposed. AD indicates autosomal dominant; 
ARVC, arrhythmogenic right- ventricular cardiomyopathy; DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; LVH, left- ventricular hypertrophy; 
LVNC, left- ventricular non compaction; and VF, ventricular fibrillation.
*FHOD3 was not curated by ClinGen due to the later publication of the reported study (Ochoa et al57). Authors demonstrate a significant excess of rare variants 
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causative variants outside of known HCM genes in 
cases with an inheritance pattern that enables triage 
and prioritization of rare variants and where the genetic 
cause of disease remains elusive after initial genetic 
testing. These cases include autosomal dominant 
HCM in large and clinically defined family pedigrees, 
although such cases are rarely encountered during 
routine clinical genetic testing. More commonly, novel 
genes underlying recessive or de novo inheritance in 
pediatric cases can be identified through sequencing 
of the patient and their unaffected parents (trio anal-
ysis) as well as other family members if available. If a 
definitive genetic cause is identified, such a research 
finding is of direct diagnostic utility. These approaches 
have recently identified recessive truncating variants 
in the ALPK3 gene as pathogenic in several pediatric 
cardiomyopathy cases.56 Taking all of these issues into 
consideration, an effective tiered approach to genetic 
testing in HCM is shown in Figure 3.
Analysis should be initially focused on validated 
HCM genes, regardless of the sequencing assay ap-
plied (gene panel or focused analysis of WGS/WES). 
If negative, the decision to expand analysis to novel 
genes (with WGS or WES) would depend on the pro-
file of the patient being tested and the likelihood of 
isolating the causative variant from genome- wide se-
quencing. For most adult probands, it is unlikely that 
pathogenic variants will be identified in genes not previ-
ously associated with HCM. In any case, as described 
subsequently, it is increasingly likely that most such pa-
tients represent non- Mendelian and nonfamilial HCM.
INTERPRETATION OF GENETIC 
FINDINGS
Determination of the clinical significance of genetic var-
iants is a complex process involving the evaluation and 
weighting of several lines of evidence. Accurate inter-
pretation is key, given the potentially detrimental con-
sequences that an erroneous interpretation can have 
on the proband and their relatives.86,87 The American 
College of Medical Genetics and the Association 
of Molecular Pathologists (ACMG/AMP) first issued 
standardized recommendations on the interpretation 
of sequence variation almost 2 decades ago,88 and a 
series of updated and increasingly articulated guide-
lines have been issued in the following years, in parallel 
with the establishment and the exponential growth of 
clinical and population sequence variation databases 
(Figure 4).
The increasing complexity of variant interpretation 
and the extent of misclassification in previous years 
underscored the need for more stringent and compre-
hensive approaches to variant classification, prompt-
ing the release of the current ACMG/AMP guidelines 
in 201589 (Figure  4). These guidelines, considerably 
more complex than previous recommendations, are 
Figure 3. Proposal for a tiered approach to genetic testing in HCM. Initial testing is restricted to validated HCM genes using 
either a targeted gene panel or a virtual panel by focused analysis of WGS or WES data.
The latter allows for reanalysis of genes subsequently linked to HCM, and WGS can detect additional variant classes including CNVs 
and deep intronic splice variants, though sequencing coverage is likely to be inferior to targeted panel sequencing. In the case of 
negative results, variant prioritization in the research setting can aid identification of the causative variant, directly translating into 
a diagnostic finding. The likelihood of detecting variation in novel genes with broader WGS/WES analysis depends on the profile of 
the patient and family being tested. In general, large pedigrees informative for segregation and trios (affected child with unaffected 
parents, indicating likely de novo variant occurrence or recessive inheritance) can enable filtering to a manageably small number of 
potentially causative variants for detailed evaluation. CNV, copy number variant; HCM, hypertrophic cardiomyopathy; WES, whole- 
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designed to be applicable to variants in all Mendelian 
genes, and to serve as a basis for more detailed and 
focused implementation for specific genes and dis-
eases. As a result, several rules embedded in the 
current interpretation framework avoid providing spe-
cific instructions on how to weight certain classes of 
evidence, inevitably giving rise to differences in ap-
proaches adopted by different laboratories and discor-
dant variant classification.90,91 For this reason, besides 
the development of automated, guideline- based vari-
ant interpretation tools,92,93 the implementation of con-
sensus guideline adaptations is now an active area of 
research, both for different evidence categories and 
for specific disorders or gene- disease pairs. Examples 
include proposals for weighting the evidence of co- 
segregation of variants with disease in pedigrees94 and 
for a more finely tuned interpretation of loss- of- function 
variants,95 quantitative scores estimating the likelihood 
of pathogenicity based on the variant location within the 
protein sequence,96 an algorithm to define a disease- 
specific population frequency cut- off for potentially 
pathogenic variants.97 More complex approaches tak-
ing into account the variant position within the three- 
dimensional structure of the protein (as opposed to 
its one- dimensional sequence) have also been used 
to identify protein regions enriched in HCM- causing 
variants,98 and could augment variant interpretation 
accuracy if embedded in the variant interpretation 
framework. For specific genes/diseases, tailored rec-
ommendations to interpret genetic variation have been 
developed for RASopathies99 and for MYH7 variants 
in HCM,100 with ongoing efforts for other genes and 
diseases by the ClinGen initiative and other groups. A 
description of ACMG/AMP guidelines’ rule- specific ap-
plication to variants detected in HCM patients, current 
issues, and ongoing/future developments toward an 
improved application are provided in Table 4.
The current guidelines are designed to minimize 
false- positive results (ie, over- calling of variant patho-
genicity) as it is usually less detrimental for patients 
and their relatives to receive an inconclusive result in 
presence of a pathogenic variant than it is to receive a 
positive result in absence of a real genetic cause. While 
assigning variants a categorical classification, guide-
lines essentially follow an underlying Bayesian frame-
work, with a variant considered “likely pathogenic” if its 
probability of pathogenicity is ≥90%, and “pathogenic” 
if ≥99%.101 However, the lack of variant- specific infor-
mation available to diagnostic laboratories for many 
rare novel variants often translates into the inability to 
correctly identify those with a probability of pathoge-
nicity ≥90%, de facto rendering the application of the 
guidelines very stringent and causing a general under- 
calling of pathogenicity.
Figure 4. Variant interpretation guidelines issued by the ACMG/AMP and independent laboratories/societies/associations 
(below the timeline) and some of the main resources contributing to a finer interpretation of sequence variants (above the 
timeline) as they became available.
Several sequence variation databases with a focus on variants’ role in disease were released in time, particularly in the late 1990s 
(eg, the Human Gene Mutation Database in 1996) but also in more recent years (eg, ClinVar in 2013). The advent of cost- effective, 
high- throughput NGS in the years between 2005 and 2010 enabled the establishment of progressively large genome- wide population 
variation databases, starting with the Pilot data set of the 1000 Genomes Project in 2009. All these increasingly complex and large- 
scale resources on one hand allow a much more detailed characterization of genetic variants, but on the other contribute to the 
constant growth in the variability and quantity of data types and information on single variants, variant classes, and genes and require 
increasingly articulated guidelines for variant interpretation. Several efforts are in place to finely tune variant interpretation in a gene- 
and disease- specific manner (eg, gene curation efforts such as ClinGen,80 established in 2015) and to render interpretation easier and 
quicker for the geneticist with automated variant interpretation tools (eg, CardioClassifier92 and CardioVAI,93 that interpret variants 
in the context of cardiomyopathies). ACMG, American College of Medical Genetics; AMP, Association for Molecular Pathology; and 
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Although this conservative approach offers the ad-
vantage of minimizing false- positive variant classifica-
tions, this inevitably comes at the cost of an increased 
rate of false negative results (ie, where pathogenic vari-
ants are classified as VUS). This drawback is partic-
ularly relevant in HCM because of its marked genetic 
heterogeneity with many variants private to affected 
families, the fact that most causative variants are mis-
sense substitutions which are inherently more difficult 
to interpret than protein- truncating variants and occur 
with higher background rates in controls, and the lim-
itations of functional assays to effectively evaluate their 
molecular effects unlike, for example, those in genes 
encoding ion channels. Recent evidence has quantified 
this false negative rate for HCM, suggesting that ≈8% 
of HCM patients who undergo clinical genetic testing 
will receive a reported VUS that is likely to be a patho-
genic variant63 (ie, a VUS in one of the 8 sarcomeric 
Table 4. Summary of the Main Lines of Evidence Used to Assess the Pathogenicity of Genetic Variants as Described by the 
ACMG/AMP Variant Interpretation Guidelines, Including Their Specific Application to Variants Detected in HCM Patients, 
Alongside Current Criteria- Specific Issues and Ongoing/Future Developments for a More Refined Application
ACMG/AMP Rule/Evidence Class Application to HCM Issues and Future Developments
PVS1—null/truncating variant in gene 
with loss- of- function mechanism for 
disease.
Applied to truncating variants in 
MYBPC3, detected in ≈10% of 
HCM patients.
1. Some variants may not lead to nonsense-mediated decay and 
haploinsufficiency.95
2. Noncoding variants that may lead to a truncated transcript (eg, 
splicing variants) can be difficult to detect and interpret.
PS1/PM5—same amino acid change/
change at same residue as an 
established pathogenic variant
Numerous established pathogenic 
HCM variants and many examples 
of different variants affecting same 
residues.
1. Difficult to unambiguously define what is an established pathogenic 
variant.
2. Curation of ClinVar entries is ongoing and will create a high 
confidence set of the most common pathogenic variants.
PS3—proven deleterious effect with 
functional studies.
Animal or cell- based studies can 
be used to assess the phenotypic 
effect of a variant detected in a 
patient.
1. Uncertainty about the translatability of evidence from in vitro or in 
vivo models to the clinical setting.
2. Currently impractical for regular application in a clinical genetic 
setting.
3. High throughput assays with demonstrated translatability for known 
pathogenic and benign variants could produce a valuable database 
for all possible single nucleotide variants in sarcomeric genes.
PS4—variant is significantly enriched 
in cases compared with controls.
There are numerous founder and 
recurrent pathogenic HCM variants 
that are observed in multiple HCM 
probands/families. Comparison 
with control or population data sets 
can identify significantly enriched 
variants.
1. Guidelines for MYH7 variants suggest presence in distinct numbers 
of HCM probands for strong (≥15), moderate (≥6) or supporting 
(≥2) evidence.100 However, this does not demonstrate statistically 
significant enrichment in cases, for which large case and control/
population data sets are required.
2. The threshold for defining a significant enrichment and methods for 
dealing with multiple testing in cohort studies need to be addressed.
3. Most currently available data sets are derived from European 
ancestry populations that are unlikely to include recurrent variants 
from other population groups.
PM1/PP2—relative frequency of 
variants in cases and controls for 
genes or gene regions.
All sarcomeric genes enriched for 
rare variants in HCM, with several 
mutation hotspots, eg, MYH7 head 
domain.
1. Current rules are ambiguously defined and not based on 
quantitative measures.
2. Methods now developed based on case-control analysis and 
definition of enriched clusters provide a quantitative approach, with 
evidence strength dependent on level of enrichment in cases.96
PM2—variant is rare enough in the 
population to be plausibly pathogenic 
(also BA1, BS1, BS2).
Population frequency data from 
gnomAD and disease- specific 
threshold based on HCM 
characteristics provide stringent 
variant rarity threshold.97
1. Low penetrance variants or modifiers may be less rare in the 
population than standard pathogenic variants, requiring evidence 
from other rules to achieve (likely) pathogenic classification.
2. Some population groups are still not well represented in databases 
like gnomAD (eg, North Africa and West Asia), variants from patients 
from these groups need to be analyzed with caution.
PP1—segregation of variant with 
disease in family pedigrees.
Segregation evidence is available 
for many HCM- causing variants 
(in literature and ClinVar). Strength 
applied to evidence depends on the 
number of informative meioses.94,100
1. As many HCM variants are private or detected in small family 
pedigrees, this evidence class will not be informative for a large 
proportion of variants.
2. Incomplete penetrance in HCM means phenotype-negative variant 
carriers are uninformative for pedigree analysis.
3. Data for this evidence can be difficult to derive from literature and 
ClinVar.
PP3—computational evidence to 
support a deleterious effect.
As with most other Mendelian 
diseases, predictions from several 
different algorithms are used to 
provide supportive evidence for 
pathogenicity.
1. Algorithms lack specificity and therefore provide limited supportive 
evidence.
2. Consensus findings from several orthogonal techniques should 
be used but there are numerous available algorithms and little 
agreement on the most appropriate subset of algorithms to use.
3. Algorithms are generically applied to all genes but may not be 
equally effective.
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genes was detected in 12.4% of HCM patients com-
pared with a background rate of rare variation of 4.3% 
in the ExAC population data set). In support of this, 
analysis of the SHaRe registry (https://thesh arere gis-
try.org/), comprising genetic data and cardiac mor-
phofunctional parameters for >9000 HCM patients), 
showed that variants classified as VUS have a mea-
surable clinical impact on outcome,102 highlighting how 
these include misclassified pathogenic variants.
In order to overcome these obstacles to variant 
interpretation, knowledge sharing between different 
centers through databases such as ClinVar (https://
www.ncbi.nlm.nih.gov/clinv ar/) is critical. As an ex-
ample, the MYH7 p.Arg869His variant had conflicting 
interpretations in ClinVar (VUS or likely pathogenic) 
based on the variant characteristics and some pub-
lished reports. However, this variant is observed at lo-
cally high frequencies in northern Tuscany (detected in 
30 of 1198 unrelated HCM probands tested at Careggi 
University Hospital compared with 0 of 356 non- HCM 
patients affected with other cardiovascular conditions, 
P=6.22×10−4), including co- segregation with dis-
ease in 7 HCM patients in a three- generation family. 
Based on this evidence (detailed in ClinVar accession 
SCV001147002.1), the MYH7 p.Arg869His variant can 
now be classified as definitively pathogenic for HCM 
and highlights the benefits of sharing findings from dif-
ferent populations and geographic regions.
The role of both public and private diagnostic lab-
oratories is key, as they represent the “hubs” where 
many novel variants are observed and where patients 
and their families are referred when a genetic cause 
of overt or suspected disease is investigated. Many 
diagnostic laboratories (such as Invitae and GeneDX) 
comprehensively publish variant interpretation sum-
maries in ClinVar, based on published data and in- 
house findings, which helped ClinVar recently reach 
the milestone of 1 million submissions. Nevertheless, 
some diagnostic companies still refuse to share data 
in this manner and instead produce proprietary variant 
interpretation that takes advantage of public resources 
such as ClinVar and gnomAD in addition to their own 
databases. Given the arduous challenge of variant in-
terpretation for genetically heterogeneous diseases like 
HCM, and the importance of accurate classification in 
clinical practice, the ethics of such practices are du-
bious. One possible solution would be for healthcare 
providers and cardiologists/clinical geneticists to insist 
on submission to ClinVar when engaging the services 
of diagnostic laboratories or only employ companies 
committed to knowledge sharing.
Data sharing initiatives are at the basis of several 
approaches that aim to tackle the high rate of in-
conclusive findings in clinical genetic testing. The 
availability of increasingly large patient and control 
cohorts may enable the development of quantitative 
statistical approaches to identify variant classes with 
high likelihood of pathogenicity. For example, case- 
control analyses can estimate these prior probabilities 
of pathogenicity through metrics such as the odds 
ratio and etiological fraction.63 A recent study using 
this approach, which defined regions of genes where 
case variants are significantly enriched and incorpo-
rated this evidence to the ACMG/AMP framework, 
increased the relative yield of clinically actionable vari-
ants in sarcomeric genes by up to 20% in HCM.96 
More comprehensive classification algorithms based 
on ensemble- or machine- learning techniques that in-
tegrate different classes of evidence may also plausi-
bly improve the accuracy of variant classification and 
contribute to lowering the proportion of inconclusive 
findings in HCM and other diseases.103,104 Advanced 
computational techniques like these may face con-
siderable hurdles though with integration into current 
guidelines as well as the workflows of clinical genetics 
laboratories.
Assays that accurately assess the functional ef-
fects of specific genetic variants, through cell- based 
or in vivo models, also offer the possibility of inform-
ing the pathogenicity of variants without the need for 
segregation evidence from large families. However, 
the lack of effective and standardized translational 
assays has limited the role for this class of evidence 
for cardiomyopathies, with the cost and time to im-
plement such assays also rendering them impracti-
cal in the context of clinical genetic screening. Novel 
techniques, in particular those using the CRISPR/
Cas9 genome editing technology, are now being ap-
plied for distinct alleles in HCM105–108 and DCM.109 
The further development of such approaches into 
more comprehensive and high- throughput assays, 
such as a recent study that functionally evaluated 
thousands of alleles in BRCA1110 simultaneously, may 
be required for such evidence to be routinely incor-
porated into clinical genetic testing.
Improvements in variant classification are espe-
cially relevant to non- white populations, which are 
characterized by significantly lower detection rates 
of (likely) pathogenic variants in cardiomyopathy pa-
tients compared with white patients.111 This is likely 
to result from the fact that the vast majority of re-
search efforts and genetic tests for cardiomyopa-
thies have been carried out on patients and controls 
of European descent (and therefore recurrent and 
founder variants occurring in whites are more likely to 
have been previously observed and characterized). 
This is emblematic of a wider problem in genetics 
research, exemplified by the proportion of genome- 
wide association studies (GWAS) performed on in-
dividuals of European descent (≈85% of the total) 
being vastly disproportionate to their proportion of 
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underscore the urgent need for more genetic re-
search to be undertaken in non- European popula-
tions as well as the further development of functional 
and quantitative approaches that reduce reliance on 
the prior observation and characterization of rare 
pathogenic variants.
The accurate interpretation of variants in HCM 
genes is equally critical when they have been de-
tected as secondary or incidental findings by WGS 
or WES in individuals undergoing genetic testing for 
noncardiac conditions. Each of the 8 core sarco-
meric HCM genes are on the list of genes recom-
mended by the ACMG to be analyzed as secondary 
findings.113 Given the relatively high rate of rare varia-
tion in these genes in the population, only those vari-
ants with strong evidence of pathogenicity should be 
considered actionable. However, as many HCM vari-
ants display reduced penetrance, clinical evaluation 
to detect the cardiomyopathy phenotype is essen-
tial, including ongoing surveillance screening where 
appropriate.114
INTERPRETATION OF GENOTYPE- 
NEGATIVE HCM
When variants in sarcomeric genes were first impli-
cated in HCM, there were indications that knowl-
edge of the causative variant might be prognostic for 
patients and potentially useful for clinical decision- 
making. For example, TNNT2 variants were initially 
shown to be associated with poor prognosis and 
high incidence of sudden cardiac death (SCD),115 
whereas variants in MYBPC3 were related with 
delayed onset of disease and more favorable out-
comes.116 Subsequently, genotype- phenotype anal-
yses on ever- larger cohorts of HCM patients have 
been undertaken to clarify these initial findings and 
attempt to identify clear and consistent correlations 
between the pathogenic variant class and the clinical 
profile and outcomes in patients.
Recent cohort studies have identified some statis-
tically significant differences in phenotype between 
patients carrying different variant classes. In particu-
lar, HCM patients with variants in thin filament genes 
(TNNT2, TNNI3, TPM1, ACTC1) were shown to have 
distinctive patterns of left- ventricular hypertrophy and 
diastolic profile, as well as lower prevalence of left- 
ventricular outflow tract obstruction (LVOTO) and late 
gadolinium enhancement (a marker of myocardial fi-
brosis) compared with those with variants in thick fil-
ament genes (MYH7, MYBPC3).117 Although patients 
with variants in thin filament genes were more likely to 
develop advanced LV dysfunction, no differences were 
observed in mortality or SCD between thin and thick 
filament variant- positive patient groups in this study.117
Studies comparing outcomes between patients 
with MYH7 and MYBPC3 pathogenic variants (the 
predominant genes associated with HCM) have 
yielded conflicting results—no significant differences 
were observed for 2 moderately sized cohorts118,119 
but in the larger SHaRe registry those with MYH7 
variants had a higher risk of advanced heart failure 
and overall composite outcome.102 Furthermore, pa-
tients with complex genotypes carrying 2 pathogenic 
mutations were at greater risk of adverse outcome 
and sudden cardiac death, irrespective of the genes 
involved. Despite these broad correlations, all of 
these studies have revealed extensive heterogeneity 
in symptoms, disease severity, and outcome, even 
among patients with the same or similar pathogenic 
variants. As a result, the individual patient’s genetic 
status has limited impact on clinical management 
and is largely limited to cascade screening and to the 
small subsets of patients with rare storage or meta-
bolic diseases mimicking HCM.
In contrast, clear and consistent differences in de-
mographics, phenotype, and outcomes have been 
observed when comparing genotype- positive and 
genotype- negative patients, that is, those with and 
without causative variants in sarcomeric genes102,118,120–
126 (Table 5).
Genotype- positive patients present approximately 
a decade earlier and unsurprisingly have a greater 
proportion of family history of both HCM and SCD. 
Maximum left- ventricular wall thickness (LVWT) is sig-
nificantly greater in genotype- positive patients, who are 
characterized by more asymmetrical hypertrophy than 
genotype- negative cases. Most important, these dif-
ferences translate into poorer outcomes for genotype- 
positive patients across a range of measures and 
composites in a number of studies, including the 4591 
cases of the SHaRe registry.102
In these studies, genotype- negative cases were de-
fined as lacking pathogenic (or potentially pathogenic, 
ie, rare and protein- altering) variants in the tested HCM 
genes (for the most part the 8 validated sarcomeric 
genes). The expectation that at least some of these 
cases may have novel genetic causes drove the many 
attempts to discover novel HCM genes, as described 
previously. However, the non- sarcomeric genes whose 
role in HCM has been validated thus far account for 
only a small proportion of HCM patients, with cumula-
tive weight of evidence now suggesting that genotype- 
negative HCM is often nonfamilial and most likely to 
represent non- Mendelian disease.
Ingles et al123 recently defined “non- familial HCM” 
as the condition that lacks both a potentially patho-
genic sarcomeric variant (whether classified as 
pathogenic or VUS) and any prior family history for 
HCM. Nonfamilial cases (which accounted for 40% of 
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from genotype- positive cases (though in a similar 
manner to overall genotype- negative patients) and 
with very low yield from cardiac clinical screening on 
first- degree relatives. Consistently, Ko et al127 found 
that only 3% of first- degree relatives of “nonfamil-
ial” probands were diagnosed with HCM by clinical 
screening, compared with 17% of relatives of pro-
bands with a positive genetic test and/or prior family 
history of HCM. As familial occurrence of HCM is still 
nonnegligible in pedigrees without an identified caus-
ative variant, current clinical recommendations state 
that regular clinical screening of family members 
should be considered for relatives in such families. 
However, the actual risk of disease in families without 
prior family history of HCM, and the consequent ne-
cessity for ongoing clinical screening in phenotype- 
negative relatives, remains uncertain. In this respect, 
it is worth emphasizing that history taking in HCM is 
a complex task due to the high variability in terms 
of age of onset and phenotype severity characteriz-
ing this condition. In contrast to other conditions in 
which the phenotype usually manifests clearly and 
penetrance is not age related, in the case of HCM 
the adoption of specific strategies to maximize pre-
cision and completeness of the information gathered 
from the proband and his/her relatives may help to 
reconstruct a reliable clinical history of the family. As 
an example, in addition to applying the principles de-
tailed in internationally accepted guidelines,114 at first 
clinical appointment the cardiologist could also ask 
for information regarding family history, so to com-
plement and confirm those gathered by the genetic 
counsellor. Furthermore, it may be good practice to 
ask patients to share a copy of all clinical documents 
regarding important clinical events such as hospital-
izations or cardiovascular events, due to the fact that 
the knowledge of family members on the cause un-
derlying such events is generally limited.
Further large- scale studies are required to definitively 
assess the risk in relatives of index cases with apparently 
nonfamilial HCM and to accurately define the criteria to 
establish family history of the disease. Such studies may 
lead to modification of current guidelines on the extent 
and frequency of clinical screening recommended for 
relatives of HCM patients, based on more accurate as-
sessments of their risk of developing disease depending 
on genetic status and family history. This may offer the 
opportunity for additional significant savings in health-
care provision and will further underscore the utility and 
cost- effectiveness of genetic testing for HCM.
FUTURE DIRECTIONS
Almost 30  years after the first definitive evidence 
of the genetic etiology of HCM,7 great progress has 
been achieved and the genes underlying the major-
ity of Mendelian monogenic cases of HCM have now 
been identified. It is clear that HCM remains essentially 
a disease of the sarcomere, characterized by reduced 
penetrance and highly variable expressivity. Although 
additional causative genes may be found, these will 
most likely explain only a minor proportion of cases, as 
demonstrated by the few non- sarcomeric genes now 
deemed validated for HCM.
Recent findings and recommendations now point 
to a more focused application of genetic testing in 
HCM. Genes of unknown significance, whose asso-
ciation with the disease remains unproven, should 
be excluded from diagnostic testing as they offer a 
negligible increase in diagnostic yield but consider-
ably increase the background noise of VUS.25,29,33,103 
Conversely, more comprehensive and focused anal-
ysis of known disease genes is likely to yield greater 
results than attempts to discover novel disease 
genes. This will include improved classification tech-
niques for coding variants and detection of variant 
classes historically considered to be of low patho-
genic potential, including intronic variants affect 
splicing, which recent research has highlighted are 
sometimes irrefutably pathogenic and could there-
fore contribute to resolving an additional proportion 
of unexplained disease cases.81,128
A large proportion of HCM cases still remain with-
out an identified causative variant, with 40% to 60% 
of screened individuals receiving an inconclusive or 
a negative test result.49,65,102,129,130 More complex ge-
netic models for HCM are increasingly believed to hold 
the answer to the majority of these genetically elusive 
cases. These are still largely unexplored and could in-
clude a polygenic model, where multiple rare variants 
cause disease when carried by the same individual but 
are benign in isolation, and complex disease model 
combining the effects of common variants of low effect 
size with nongenetic factors such as hypertension and 
obesity. However, investigations into such models have 
so far been limited by the lack of availability of case 
and control cohorts large enough to reach satisfactory 
statistical power. To date, the only GWAS reported for 
HCM comprised 174 patients and 823 controls, and 
detected a significant association between a common 
intronic variant in the FHOD3 gene on chromosome 
18 and the presence of disease.131 Such efforts will be 
increasingly possible as single centers are more eas-
ily able to sequence large numbers of patients, and 
through publicly accessible (though with variable data 
access policies) phenotyped and sequenced popula-
tion cohorts such as those by the National Institutes 
of Health (the ongoing “All of us” research program 
that aims at 1  million genomes, and the dbGap da-
tabase132), the UK Biobank,133 Genomics England134 
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Such data sets, coupled with data sharing efforts such 
as the SHaRe Registry, will plausibly enable inves-
tigations on multi- genic and other complex disease 
models.
The lack of clear correlation between the genetic and 
clinical status of patients has until now dented hopes for 
the development of personalized medicine approaches, 
with genetic testing results still being used in a strictly 
diagnostic (rather than predictive) fashion. The incom-
plete penetrance of pathogenic sarcomeric variants, and 
the variable phenotypic expression in variant carriers, 
indicates that other genetic and non- genetics factors 
are likely to influence the development of disease. It has 
been observed that the presence of multiple rare sarco-
meric variants has a cumulative effect on disease onset 
and incidence of events, regardless of the variants’ di-
agnostic classification (ie, even when the variants could 
not be classified as disease- causing),136 even though 
previous studies on multiple co- occurring sarcomeric 
mutations in HCM likely overestimated the pathogenicity 
of the individual variants.137,138 This suggests that variants 
that are not pathogenic in isolation may act to modify 
and exacerbate the disease phenotype in presence of 
a disease- causing allele. Research into the full range of 
genetic factors that may interact with primary sarcomeric 
mutations to influence phenotype is at an early stage 
but is promising—such factors could include common, 
low frequency, and rare variants that add to the muta-
tional burden, act as protective variants, or regulate the 
ratio of expression of mutated and wild- type alleles.139 
Identifying these factors through large- scale genome- 
wide association studies and WGS, and integrating such 
a genetic profile of common and rare variants with known 
nongenetic modifying factors such as hypertension and 
obesity, offers the promise in the near future of improved 
risk prediction for HCM patients and their relatives and a 
more personalized approach to clinical care.
CONCLUSIONS
The path to a complete and detailed understanding 
of how genetic variants cause HCM and determine its 
severity will be long and challenging. Three major chal-
lenges remain unresolved and need to be addressed:
1. The still suboptimal accuracy of variant interpre-
tation strategies,
2. The scarcity of clear genotype-phenotype correla-
tions, and
3. The necessity to expand research on genetic causes 
of HCM beyond the monogenic Mendelian inherit-
ance model.
Advances in our understanding of population ge-
netics, the development of new functional genomics 
techniques and quantitative approaches to variant in-
terpretation, data sharing of cohort data and evidence 
from clinical genetics laboratories, and the introduction 
of new standards for assessing gene and variant patho-
genicity have all greatly improved our understanding of 
the Mendelian genetics of HCM.
Genetic testing can now be more rigorously and 
consistently applied for HCM patients, enabling the ac-
curate identification of primary causative variants and 
at- risk individuals.
Our understanding of the more complex genetics 
that may underlie both the highly variable phenotypes 
observed in sarcomeric variant carriers and the ge-
netic basis of currently genotype negative and likely 
non- Mendelian HCM is still at an early stage. It is likely 
that significant investment in sequencing and pheno-
typing, and further initiatives in developing international 
registries and consortia, will be essential for allowing 
us to make similar progress in understanding the com-
plex genetics underlying HCM.
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GENE YEAR PMID CLINGEN CLASSIFICATION
ACTA1 2006 16945537 No evidence (isolated HCM)
ACTC1 1999 10330430 Definitive (isolated HCM)
ACTN2 2010 20022194 Moderate (intrinsic cardiomyopathy gene - isolated HCM)
ANKRD1 2009 19608031 Limited (isolated HCM)
BRAF 2012 22589294 NA
CACNA1C 2014 24183960 Definitive (Timothy syndrome - syndromic conditions where isolated HCM may be seen)
CALR3 2007 17655857 Limited (isolated HCM)
CASQ2 2007 17655857 No evidence (isolated HCM)
CAV3 2004 14672715 Definitive (Caveolinopathy - syndromic conditions where left-ventricular hypertrophy is seen only with overt systemic features)
COX15 2003 12474143 Strong (Leigh syndrome - syndromic conditions where left-ventricular hypertrophy is seen only with overt systemic features)
CRYAB 2013 23197161 Definitive (Alpha-B crystallinopathy - syndromic conditions where left-ventricular hypertrophy is seen only with overt systemic features)
CSRP3 2003 12642359 Moderate (isolated HCM)
DES 2006 16585054 Definitive (Desminopathy - syndromic conditions where isolated HCM may be seen)
FHL1 2012 22923418 Definitive (Emery-Dreifuss muscular dystrophy - syndromic conditions where isolated HCM may be seen)
FHL2 2014 25358972 NA
FXN 2005 15936968 Definitive (Friedrich ataxia - syndromic conditions where left-ventricular hypertrophy is seen only with overt systemic features)
GAA 2012 22555271 Definitive (Pompe disease - syndromic conditions where left-ventricular hypertrophy is seen only with overt systemic features)
GLA 2012 22336178 Definitive (Fabry disease - syndromic conditions where isolated HCM may be seen)
JPH2 2007 17509612 Moderate (isolated HCM)
KCNQ1 2014 24183960 No evidence (isolated HCM)
KLF10 2012 22234868 Limited (isolated HCM)
LAMP2 2011 21896538 Definitive (Danon disease - syndromic conditions where isolated HCM may be seen)
LDB3 2006 17097056 Definitive (Myofibrillar myopathy - syndromic conditions where left-ventricular hypertrophy is seen only with overt systemic features)
LMNA 2013 23785128 NA
MAP2K1 2012 22589294 NA
MAP2K2 2012 22589294 NA
MRPL3 2011 21786366 NA
MYBPC3 1990 1975599 Definitive (isolated HCM)
MYH6 2002 11815426 Limited (isolated HCM)
MYH7 1989 2811944 Definitive (isolated HCM)
MYL2 1996 8673105 Definitive (isolated HCM)
MYL3 1996 8673105 Definitive (isolated HCM)
MYLK2 2001 11733062 Limited (isolated HCM)
Table S1.  List of genes with ≥1 variant implicated in HCM in the Human Gene Mutation Database (HGMD) version 2016.3, alongside year of first published 
association with HCM and relative publication (PubMed ID), and gene classification by the ClinGen curation effort 
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MYO6 2004 15060111 Definitive (Bilateral hearing loss - syndromic conditions where left-ventricular hypertrophy is seen only with overt systemic features)
MYOM1 2011 21256114 Limited (isolated HCM)
MYOZ2 2007 17347475 Limited (isolated HCM)
MYPN 2010 20801532 Limited (isolated HCM)
NEBL 2016 27186169 NA
NEXN 2010 20970104 Limited (isolated HCM)
OBSCN 2007 17716621 Limited (isolated HCM)
PDLIM3 2010 20801532 Limited (isolated HCM)
PKP2 2015 26332594 NA
PLN 2015 26573135 Definitive (intrinsic cardiomyopathy gene - isolated HCM)
PRKAG2 2001 11371514 Definitive (PRKAG2 cardiomyopathy - syndromic conditions where isolated HCM may be seen)
PTPN11 2012 22555271 Definitive (Noonan syndrome - syndromic conditions where isolated HCM may be seen)
RAF1 2007 17603483 Definitive (Noonan syndrome - syndromic conditions where isolated HCM may be seen)
RIT1 2014 24901346 Definitive (Noonan syndrome - syndromic conditions where isolated HCM may be seen)
RYR2 2015 26573135 Limited (isolated HCM)
SCN5A 2016 26656175 NA
SGCD 2007 17652892 NA
SLC25A4 2005 16155110 Definitive (Mitochondrial disease - syndromic conditions where left-ventricular hypertrophy is seen only with overt systemic features)
SOS1 2012 22555271 NA
SRI 2004 16118855 NA
TCAP 2004 15582318 Limited (isolated HCM)
TNNC1 2001 11371514 Moderate (isolated HCM)
TNNI3 1997 9241277 Definitive (isolated HCM)
TNNT2 1994 8205619 Definitive (isolated HCM)
TPM1 1994 8205619 Definitive (isolated HCM)
TRIM54 2014 24865491 NA
TRIM55 2014 24865491 NA
TRIM63 2012 22821932 Limited (isolated HCM)
TTN 1999 10462489 Limited (isolated HCM)
TTR 2015 25611685 Definitive (Transthyretin amyloidosis - syndromic conditions where isolated HCM may be seen)
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